PDS Biotechnology (PDSB) News Today $1.38 +0.05 (+3.76%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.39 +0.01 (+0.72%) As of 05/2/2025 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period PDS Biotechnology price target lowered to $5 from $7 at B. RileyApril 26, 2025 | markets.businessinsider.comB. Riley Predicts Stronger Earnings for PDS BiotechnologyPDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Stock analysts at B. Riley increased their Q1 2025 earnings per share (EPS) estimates for PDS Biotechnology in a note issued to investors on Monday, April 21st. B. Riley analyst M. Mamtani now forecasts that the company will post earnings of ($0April 26, 2025 | marketbeat.comQ1 EPS Forecast for PDS Biotechnology Increased by AnalystApril 26, 2025 | americanbankingnews.comPDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2025 | globenewswire.comPDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual MeetingApril 16, 2025 | globenewswire.comPDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025April 8, 2025 | globenewswire.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comAlliance Global Partners Remains a Buy on PDS Biotechnology (PDSB)March 29, 2025 | markets.businessinsider.comPDS Biotechnology price target lowered to $13 from $21 at H.C. WainwrightMarch 27, 2025 | markets.businessinsider.comPDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays BearishMarch 27, 2025 | msn.comPDS Biotechnology Corporation: PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs UpdateMarch 27, 2025 | finanznachrichten.dePDS Biotechnology Corporation CEO to Present at 2025 CAGLA NeauxCancer Conference in New OrleansMarch 27, 2025 | nasdaq.comA Look at PDS Biotechnology's Upcoming Earnings ReportMarch 27, 2025 | benzinga.comPDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comPDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs UpdateMarch 27, 2025 | globenewswire.comPDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer ConferenceMarch 25, 2025 | globenewswire.comPDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | uk.finance.yahoo.comShort Interest in PDS Biotechnology Co. (NASDAQ:PDSB) Grows By 20.7%PDS Biotechnology Co. (NASDAQ:PDSB - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 4,670,000 shares, an increase of 20.7% from the February 13th total of 3,870,000 shares. Based on an average daily volume of 630,100 shares, the days-to-cover ratio is presently 7.4 days. Approximately 13.8% of the shares of the stock are short sold.March 19, 2025 | marketbeat.comPDS Biotechnology (PDSB) Expected to Announce Quarterly Earnings on WednesdayPDS Biotechnology (NASDAQ:PDSB) will be releasing earnings before the market opens on Wednesday, March 26, Financial Modeling Prep reports.March 19, 2025 | marketbeat.comPDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial ResultsMarch 18, 2025 | globenewswire.comPDS Biotech announces FDA clearance of IND apprlication for Versamune MUC1 comboMarch 13, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Cartesian Therapeutics (RNAC)March 13, 2025 | markets.businessinsider.comPDS Biotech gets IND application clearance for colorectal cancer treatmentMarch 13, 2025 | msn.comPDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal CancerMarch 13, 2025 | globenewswire.comPDS Biotech Leadership to Participate in March ConferencesMarch 11, 2025 | globenewswire.comPDS Biotechnology initiates VERSATILE-003 Phase 3 trial of Versamune HPVMarch 7, 2025 | markets.businessinsider.comPDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck CancerMarch 7, 2025 | globenewswire.comPDS Biotechnology prices 7.33M shares at $1.50 in registered direct offeringFebruary 27, 2025 | markets.businessinsider.comPDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesFebruary 27, 2025 | globenewswire.comPDS announces data on survival, clinical responses in HPV-associated cancersFebruary 27, 2025 | markets.businessinsider.comPDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA OncologyFebruary 26, 2025 | globenewswire.comPDS Biotechnology announces circulating tumor DNA results for Versamune HPVFebruary 24, 2025 | markets.businessinsider.comPDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer ResearchFebruary 24, 2025 | globenewswire.comPDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025February 20, 2025 | globenewswire.comWitnessing the birth of planets: Webb telescope provides unprecedented view into PDS 70 systemFebruary 12, 2025 | msn.comPDSB stock touches 52-week low at $1.3 amid market challengesFebruary 12, 2025 | msn.comPDS Biotechnology (NASDAQ:PDSB) Shares Down 5.8% - What's Next?PDS Biotechnology (NASDAQ:PDSB) Shares Down 5.8% - Should You Sell?February 8, 2025 | marketbeat.comPDS Biotechnology reaffirms guidance for Q1 initiation of VERSATILE-003February 6, 2025 | markets.businessinsider.comPDS Biotech set for Phase 3 trial in HPV-positive cancer treatmentFebruary 6, 2025 | msn.comPDS Biotechnology Co. (NASDAQ:PDSB) Shares Sold by Inspirion Wealth Advisors LLCInspirion Wealth Advisors LLC trimmed its position in shares of PDS Biotechnology Co. (NASDAQ:PDSB - Free Report) by 78.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 73,532 shares of the company's stock after sellingJanuary 17, 2025 | marketbeat.comPDS Biotechnology (PDSB) Receives a Buy from Alliance Global PartnersDecember 20, 2024 | markets.businessinsider.comPDS Biotechnology (NASDAQ:PDSB) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $21.00 price target on shares of PDS Biotechnology in a research note on Wednesday.December 18, 2024 | marketbeat.comPDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 6, 2024 | globenewswire.comPDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ETDecember 3, 2024 | globenewswire.comB. Riley Cuts Earnings Estimates for PDS BiotechnologyPDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - B. Riley dropped their FY2024 earnings estimates for shares of PDS Biotechnology in a report released on Monday, November 25th. B. Riley analyst M. Mamtani now expects that the company will post earnings of ($1.12) per share for the year, down fNovember 27, 2024 | marketbeat.comStrategic Changes in PDS Biotechnology’s Clinical Trial Design Position Stock as Attractive Buy OpportunityNovember 26, 2024 | markets.businessinsider.comPDS Biotechnology Shares Down 18% After Phase 3 Trial ModificationsNovember 15, 2024 | marketwatch.comPDS Biotechnology Highlights Clinical Progress and Q3 ResultsNovember 15, 2024 | markets.businessinsider.comPDS Biotechnology: Strategic Advancements and Clinical Progress Drive Buy RatingNovember 15, 2024 | markets.businessinsider.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | msn.com Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Email Address PDSB Media Mentions By Week PDSB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PDSB News Sentiment▼0.000.73▲Average Medical News Sentiment PDSB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PDSB Articles This Week▼02▲PDSB Articles Average Week Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PLX News Today KOD News Today SLRN News Today AARD News Today PRME News Today SOPH News Today NGNE News Today CRGX News Today AMRN News Today ANNX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PDSB) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PDSB Stock Free PDSB Stock Alerts